Jan 28, 2026
January 21, 2026
In response to the rapidly rising prevalence of myopia among children and adolescents worldwide, and the growing demand for personalized, evidence-based intervention strategies, Akeso Eyecare has entered a clinical research partnership with the Shanghai Eye Disease Prevention and Treatment Center.
On January 21, 2026, the two organizations officially launched a randomized controlled clinical study (RCT) to evaluate the effectiveness, safety, and wearing comfort of MetaRx™ lithography-based microstructure myopia management lenses. The study marks a key milestone in Akeso’s clinical validation roadmap, translating semiconductor-grade lithography technology into rigorously tested ophthalmic applications.
The initiative is promoted by the Yangtze River Delta Ophthalmic Disease Prevention and Treatment Specialist Alliance, with the objective of establishing high-quality clinical evidence to support precision, individualized myopia control in pediatric populations.
The study is conducted under the clinical leadership of:
This study builds on an earlier collaboration initiated on June 6, 2025, during the 4th Yangtze River Delta Eye Health Conference, where Akeso and the Shanghai Eye Disease Prevention and Treatment Center formally launched structured clinical research on MetaRx™ lithography technology in pediatric myopia control.
That milestone marked Akeso’s entry into large-scale, standardized clinical validation, laying the foundation for the present randomized controlled trial.
The study adopts a prospective, single-center, randomized, double-blind, controlled (RCT) design, enrolling 252 myopic children and adolescents aged 6–14 years.
Clinical outcomes are assessed through scheduled follow-ups, including:
To enhance data integrity, clinical measurements are combined with smart spectacle frame data, enabling real-time monitoring of:
This integrated approach allows for a comprehensive evaluation of effectiveness, safety, comfort, and real-world usability.
Within the study, Akeso provides core technological support, ensuring that advanced lithographic lens designs are precisely manufactured and consistently reproduced under strict clinical research standards.
During the project briefing, Mr. Luo Shihong, Medical Director of Akeso, systematically introduced the company’s MetaRx™ lithography technology and the lens designs applied in the study.
MetaRx™ lithography applies semiconductor-grade lithography technology across disciplines to ophthalmic lens manufacturing, breaking through the limitations of traditional “mold injection + CNC lathe” processes. This innovation improves microlens dimensional accuracy by 20 times, achieving nanometer-level precision manufacturing.
The technology:
These capabilities form the technical foundation for precision-based myopia management solutions evaluated in the clinical study.
Akeso’s MetaRx™ lithography technology holds multiple intellectual property patents and has been recognized as one of the “Top Ten Original Ophthalmic Innovations in China (2024)”.
This recognition reflects the technology’s originality, translational value, and clinical relevance, reinforcing its role as a meaningful advancement within the ophthalmic industry.
At the study launch, Dr. Cai Xiaogu, Founder and CEO of Akeso, emphasized the importance of deep medical–industry collaboration in advancing myopia management from concept to clinical reality.
He highlighted Akeso’s commitment to providing robust and reproducible optical technologies, supporting high-quality clinical research, and accelerating the evidence-based adoption of precision myopia solutions.
The collaboration represents a broader strategic vision: integrating advanced industrial technologies with ophthalmic medicine to shift myopia control from standardized interventions toward precision-based prevention, delivering scalable, clinically validated benefits for children and adolescents.
Akeso Eyecare is a doctor-founded eye-technology company and CDMO focused on improving vision care. We design and build advanced solutions like AR displays for myopia prevention, eye tracking, extended reality devices, and digital vision health tools used in eye care and smart technology.
Our mission is to improve global vision health through smart innovation. By combining optical design, materials science, and AI, our R&D team supports partners from early research to custom design, manufacturing, and large-scale production, always guided by medical expertise, collaboration, sustainability, and patient-first thinking.
Akeso – engineering the future of vision.
Engineering the
Future of Vision.